Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share
Supporting the Safe, Effective and Efficient Use of UV-C Disinfection in Healthcare and Beyond

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

UV-C light has been part of disinfection processes in healthcare settings for some time. Now, it’s becoming an essential tool in other environments as a safe and fast way to kill pathogens. But using UV-C effectively requires users to know if they’ve delivered a sufficient dose of irradiation to a variety of surfaces – and that can be difficult because UV-C is, in practical terms, an invisible tool.

Since the beginning of the pandemic, the world is acutely aware that infection control isn’t just for hospitals. Discussing these new use cases and how UV-C works, host Daniel Litwin spoke with Wendy Brady, Director of Global Marketing for Intellego Technologies.

“Pathogens are everywhere on the surfaces we touch and the air we breathe. UV-C can be an important tool to protect spaces outside of healthcare,” Brady said. But the key to successful UV-C disinfection is ensuring that you’ve delivered the right amount of ultraviolet irradiation to surfaces.

So, how exactly does UV-C light work?

“UV-C is part of the ultraviolet spectrum and it has a powerful germicidal effect on bacteria, viruses and fungi,” Brady explained. “The way it works is by breaking the DNA or RNA bonds in organisms so they can then no longer reproduce. It renders them inactive, but a sufficient amount of energy or irradiation must be delivered to surface in order to achieve a germicidal effect.”

With established and widespread use in hospitals, other industries are now looking to the technology to help combat pathogens and make public areas safer. Brady said that schools, airports, hotels, event venues, commercial office buildings and more are all beginning to employ different types of UV-C systems to provide a higher level of sanitization.

Because UV-C is often used in unoccupied spaces or in closed cabinet systems, it’s challenging for operators to know if their device is truly working and that all target areas have received enough irradiation to achieve sanitization. It’s not something they can see, but dosimeters provide that important piece of visible evidence.

UVC Dosimeters have a color-changing indicator area that shows the ‘dose’ or how much germicidal irradiation has been delivered. By seeing the dose, measured as 25, 50 or 100 mJ/cm², a person can verify that the device has delivered enough energy needed to kill SARS-CoV-2, MRSA or even C. Difficile,” Brady said.

With a dosimeter, users have accurate, visible confirmation and real-time evidence that a UV-C disinfection device has done its job. With this additional context, disinfecting can become a more efficient process and it builds confidence in the effectiveness of the technology.

“Dosimeters can also save time, as users can see when the disinfection cycle is successful. Operators are finding that some areas can be sanitized more quickly than expected because they can see when they’ve reached a target dose. This means they can use their UV-C equipment in a more efficient manner, sanitizing more areas and creating safer environments,” Brady added.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale

Facebook – facebook.com/marketscale

LinkedIn – linkedin.com/company/marketscale

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com’s $220M round makes imaging an API contract for plans and employers

Scan.com closed $220 million in equity and debt. It’s expanding its U.S. imaging network plus API-based scheduling and results delivery. For health plans and employers, imaging is starting to look like a platform procurement and integration decision, not a directory problem.

  • 01If imaging access is bought via an API, the real spec becomes integration depth: two-way scheduling plus results routing into the EMR, according to Business Wire.
  • 02Scan.com’s mix of $90M equity and $130M debt earmarked for M&A and working capital points to a fast-changing imaging provider network, which can help access but demands discipline in contracting and integration testing.
  • 03The same week’s funding news for Elucid ($55M) suggests AI imaging vendors will keep pushing toward FDA-cleared workflow insertions, a different buying path than network-layer platforms.

Sep 4, 2026

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitors pitch audit-ready, AI-ready device platforms

MD&M West 2026 exhibitor messaging suggests compliance testing and AI-ready compute are becoming early decisions, not afterthoughts. Medical Economics described 2026 as a period shaped by rapid technological change, regulatory scrutiny and ongoing economic uncertainty. Medical Design & Outsourcing’s MD&M West 2026 preview points to exhibitors highlighting test equipment, contract manufacturing and other launch support services.

  • 01If a device roadmap includes AI features, the critical path shifts toward data and software evidence that regulators can audit, which means earlier lock-in of compute platforms and test plans, pulling verification and validation into supplier selection.
  • 02MD&M West exhibitor messaging suggests verification and validation capacity is becoming a procurement problem, with rentals and lab-ready gear positioned as a way to avoid booking delays and re-tests, according to Medical Design & Outsourcing.
  • 03With imaging and other new procedural and device concepts moving fast, manufacturing leaders should expect more frequent line-change decisions and component qualification work, as GE HealthCare's photon-counting CT CE mark reported by MedTech Dive and MDDI's New Technologies coverage illustrate.

Sep 3, 2026

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz - Cancer Survivor and Chief Medical Physicist

Dr. Dana Rosencranz brings 23+ years of experience as chief medical physicist at Texas Oncology and personal insight as a breast cancer survivor, enabling her to guide patient support groups and advocate for accessible cancer care. She emphasizes AI's potential in auto-contouring and treatment planning while stressing the need for proper training, validation, and transparency before implementation.

  • 01Over 23 years at Texas Oncology integrating personal cancer survivor experience with clinical expertise to improve patient empathy and support group leadership
  • 02AI in oncology requires human oversight, validation, and transparency; auto-contouring and auto-planning must be combined with staff training and rigorous protocol testing before deployment
  • 03Texas Oncology prioritizes offering state-of-the-art cancer treatments closer to home, including for rural patients, to reduce travel and ensure consistent, personalized care

Sep 3, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512